抗血管生成药物联合免疫检查点抑制剂治疗晚期非小细胞肺癌的效果与安全性

打开文本图片集

Efficacy and Safety of Anti-angiogenic Drugs Combined with Immune Checkpoint Inhibitor in the Treatment of Advanced Non-small Cell Lung Cancer/TANG Sai.//Medical Innovation of China， 2025， 22（29）：110-114

[Abstract] Objective： To investigate the eficacy and safety of anti-angiogenic drugs combined with immune checkpoint inhibitorinthe treatment of advancednon-smallcellung cancer（NSCLC）.Method：A totalof90 patients with stage IV NSCLC who had not received prior chemotherapy or with recurrent metastatic NSCLC were enrolled in Yichun People's Hospital Cancer Hospital from March 2O22 to March 2O23，they were divided into group A （ n=. 30，treated with Anlotinib combined with Camrelizumab），group B（ n =30，treated with Recombinant Human Endostatin combined with Camrelizumab） and group C （ n =30，treated with Camrelizumab） according to the drug use. The clinical eficacy，qualityof life，serum vascular endothelial growth factor （VEGF）levels and adverse reactions of thethree groups were compared.Result： There were no statisticall significant diferences inobjective response rate and disease control rate between group A and group B （ P >0.05）. The objective response rate of group A and group B was higher than that of group C （ P <0.05）.There was no statistically significant difference in the overall improvement rate between group A and group B （ Pℓ >0.05）. The overall improvement rate of group A and group B was higher than that of group C （ P <0.05）.There was no statistically significant difference in VEGF levels among the three groups before treatment （ P> 0.05）.After6 weeks of treatment，the VEGFlevels in the three groups decreased，and the VEGF level in group A and group B waslower than that in group C （ P <0.05）. There was no statistically significant difference in the incidence of adverse reactions among the three groups （ P>0.05 ）.Conclusion： The combination of anti-angiogenic drugs and immune checkpoint inhibitor has a better therapeutic efect on advanced NSCLC， which can improve the quality of life of patients and reduce the levels of serum VEGF.

[Keywords]Anti-angiogenic drugsImmune checkpoint inhibitorAdvanced non-smallcellung cancer First-author'saddress：WardI，YichunPeople's HospitalCancerHospital，Yichun 336ooo，China doi： 10.3969/j.issn.1674-4985.2025.29.026

晚期非小细胞肺癌（NSCLC）患者因耐药、肿瘤异质性、转移复发、免疫相关不良反应、耐受性差等原因，导致治疗难度较大。（剩余5514字）